Department of Orthopaedic Surgery, Washington University in St. Louis, St. Louis, MO, USA.
Spine (Phila Pa 1976). 2010 Apr 1;35(7):747-53. doi: 10.1097/BRS.0b013e3181bc3420.
Consecutive case series.
The purpose of this study was to analyze the pseudarthrosis rate in a large series of recombinant human bone morphogenetic protein-2 (rhBMP-2) augmented multilevel (> or =3 levels) anterior cervical fusions.
The reported pseudarthrosis rate following anterior cervical fusion varies from 0% to 20% for single-level and up to 50% for multilevel fusions. It has been postulated that the use of rhBMP-2 may decrease the pseudarthrosis rate.
A consecutive series of patients with cervical spondylosis and/or disc herniation who underwent anterior cervical fusion with rhBMP-2, structural allograft, and plate fixation with a minimum 2-year follow-up were analyzed by experienced, independent spine surgeons.
A total of 127 patients (54 men and 73 women with mean age of 54 +/- 10 years [range, 32-79]) were examined. Seventy-five (59.1%) patients underwent a 3-level fusion, 34 (26.7%) underwent a 4-level fusion, and 18 (14.2%) underwent a 5-level fusion. Of the 451 fusion segments, 14 segments (3.1%) in 13 of 127 patients (10.2%) had evidence of pseudarthrosis at 6 months following surgery. Of the 13 patients with a pseudarthrosis, 3 had a 3-level fusion (3/75 patients [4.0%]), 6 had a 4-level fusion (6/34 patients [17.4%]), and 4 had a 5-level fusion (4/18 patients [22.2%]). Five patients were asymptomatic and were not revised, but the remaining 8 patients required additional surgery. In 12 of 13 patients with a pseudarthrosis, the nonunion occurred at the lowest fusion level and at the cervicothoracic junction. The only statistically significant risk factor for developing a pseudarthrosis was the number of fusion levels.
In a large series of rhBMP-2 augmented multilevel fusions, the pseudarthrosis rate was 10.2% at 6 months following surgery. Since the risk of pseudarthrosis increases with the number of fusion levels, a long fusion lever arm may biomechanically overwhelm the biologic advantage of rhBMP-2. While rhBMP-2 is known to enhance fusion rates, it does not guarantee fusion in all situations.
连续病例系列。
本研究的目的是分析在大量使用重组人骨形态发生蛋白-2(rhBMP-2)增强的多节段(≥3 节段)前路颈椎融合术中假关节形成率。
前路颈椎融合术后假关节形成率报道为单节段 0%至 20%,多节段融合术达 50%。据推测,rhBMP-2 的使用可能会降低假关节形成率。
由经验丰富的独立脊柱外科医生对接受 rhBMP-2、结构性同种异体移植物和钢板固定的颈椎前路融合术的连续系列患者进行分析,这些患者均接受了至少 2 年的随访。
共 127 例患者(54 例男性,73 例女性,平均年龄 54±10 岁[范围 32-79 岁])接受了检查。75 例(59.1%)患者行 3 节段融合术,34 例(26.7%)患者行 4 节段融合术,18 例(14.2%)患者行 5 节段融合术。在 451 个融合节段中,术后 6 个月时,13 例(10.2%)中的 14 个节段(3.1%)有假关节形成。在 13 例假关节形成的患者中,3 例为 3 节段融合术(3/75 例患者[4.0%]),6 例为 4 节段融合术(6/34 例患者[17.4%]),4 例为 5 节段融合术(4/18 例患者[22.2%])。5 例患者无症状且未行翻修,但其余 8 例患者需要进一步手术。在 13 例假关节形成的患者中,12 例假关节发生在最低融合水平和颈椎胸段交界处。发生假关节形成的唯一具有统计学意义的危险因素是融合节段的数量。
在大量使用 rhBMP-2 增强的多节段融合术中,术后 6 个月的假关节形成率为 10.2%。由于假关节形成的风险随着融合节段数量的增加而增加,长融合杠杆臂可能会在生物力学上超过 rhBMP-2 的生物学优势。虽然 rhBMP-2 已知能提高融合率,但并不能保证在所有情况下都能融合。